Quantum Computing Targets Improved Human Aging and Longevity in new Agreement between Allosteric Bioscience and Polaris Quantum Biotech

February 3, 2022, Allosteric Bioscience, Inc., a company founded in 2021
to integrate Quantum Computing and Artificial Intelligence with various Biomedical sciences to create improved treatments for Aging, Longevity and Aging related diseases and Polaris Quantum Biotech, a company at the vanguard of Quantum Computing for drug discovery, have signed a collaboration agreement.  Together, the companies are utilizing advancements in Quantum Computing and Artificial Intelligence in biomedical disciplines for discovery and development of novel pharmaceuticals.

Improved Aging, Longevity and Aging related diseases is a lead program at Allosteric Bioscience and the focus of this new agreement. This agreement is also supported by an equity investment in Polarisqb. This agreement initiates a joint program involves using Quantum Computing and advanced artificial intelligence (AI) technology for creation of an inhibitor of a key protein involved in human Aging and Longevity. This program’s goal is to significantly improve the normal human Aging and Longevity process which could have benefits for global health that represents a multibillion-dollar global market. Allosteric Bioscience believes that the power of Quantum Computing and advanced AI are a powerful combination for the creation of pharmaceuticals targeting toxic pathways which have been difficult to generate in the past.

Allosteric Bioscience is using its “QAB” platform which involves integrating Quantum Computing and advanced AI with Biomedical sciences such as genetics, genomics, system biology, epigenetics, systems biology, proteomics and other disciplines. The company is also employing two Aging platforms: “ALT” - Aging Longevity Targets and “ALM” – Aging Longevity Modulators of the Targets which have the potential for regulating and improving the Aging and Longevity process.

Dr. Shahar Keinan, CEO and co-Founder of Polarisqb stated, “Quantum Computing technology is coming of age, allowing us to revolutionize drug discovery timelines and budgets, while improving the overall profile of the designed drugs. We are excited about the joint program with Allosteric tackling Aging and Longevity using Polarisqb‘s Tachyon platform. The application of Quantum Computers to solving these complex questions is truly extraordinary.

Dr. Arthur P. Bollon, President and co-Founder of Allosteric Bioscience stated, “The agreement between Allosteric Bioscience and Polarisqb represents an important milestone in implementing the Allosteric Bioscience strategy of integrating the Quantum Computer and advanced AI with various biomedical sciences for creation and development of new and advanced treatments for Improved Aging, Longevity and Aging related diseases.”

Polaris Quantum Biotech, a leader in Quantum Computing for drug discovery, has created the first drug discovery platform built on a Quantum Computer. Founded in 2020 by Shahar Keinan, CEO, and Bill Shipman, CTO, Polarisqb uses the latest cloud, quantum computing, artificial intelligence, and machine learning to process, evaluate and identify drug lead molecules 10,000 times faster than alternative solutions. With real-time adaptability, Polarisqb plans to produce up to 100 drug leads annually. The resulting high-quality drug lead will be taken to synthesis, testing, and licensed to pharmaceutical partners for further development within months, rather than years. Additional information is available at www.Polarisqb.com

Allosteric Bioscience founders, Bruce Meyers, Arthur P. Bollon, Ph.D., and Peter Sordillo, Ph.D., M.D., have decades of expertise in the biotechnology industry as well as biomedical sciences including genomics, epigenetics, systems biology, proteomics as well as oncology and quantum physics. Bruce Meyers and Dr. Bollon, who has expertise in genomics and epigenetics, have co-founded/founded multiple biotechnology companies including Cytoclonal Pharmaceutics (where Dr. Bollon was Chairman and CEO) which was merged to create OPKO Health, a NASDAQ traded company with a present market cap of $2 billion.  Dr. Sordillo, who has a background in quantum information theory and quantum computers, is considered a leader in treating sarcomas and other cancers and has managed over 50 clinical trials at leading clinical institutions including Sloan Kettering Cancer Center.